Document is current
Any future updates will be listed below
-
Authors
Zhang, Jingzhou
DeMeo, Dawn L.
Silverman, Edwin K.
Make, Barry J.
Wade, R. Chad
Wells, J. Michael
Cho, Michael H.
Hobbs, Brian D. http://orcid.org/0000-0001-9564-0745
-
Funding
Funding for this research was provided by:
National Institutes of Health (K08 HL136928, U01 HL089856, R01 HL147148, R01 HL135142)
National Institutes of Health (R01 HL135142, R01 HL137927, R01 HL089856, R01 HL147148, R01HL148215, UH3TR002450)
- License Information
-
More Information
Article History
Received: 28 December 2020
Accepted: 6 July 2021
First Online: 14 July 2021
Declarations
:
: Institutional review board (IRB) approval was obtained at each of the participating study centers (Additional file InternalRef removed) prior to study initiation. All participants provided written informed consent.
: Not applicable.
: JZ reports no conflict of interest. DLD reports grant support from Bayer and honoraria from Novartis. EKS reports grant support from GlaxoSmithKline and Bayer. BJM reports funding from the NHLBI for the COPDGene study; grants and medical advisory boards from Boehringer Ingelheim, GlaxoSmithKline, AstraZeneca, and Sunovian; grant from Pearl; consultant for Third Pole; personal fees for DSMB from Spiration and Shire/Baxalta; CME fees from Projects in Knowledge, Wolter Kluwer Health, Eastern Pulmonary Society, National Jewish Health and Novartis; Medical advisory boards from Theravance, Novartis, Phillips, Science 24/7, and Verona. RCW reports no conflict of interest. JMW reports research support from Bayer AG, Mereo BioPharma, and Vertex Pharmaceuticals; and consulting for Mereo BioPharma, GlaxoSmithKline, AstraZeneca, and Boehringer Ingelheim. MHC reports grant funding from GSK and Bayer and consulting and speaking fees from Illumina and AstraZeneca. BDH reports no conflict of interest.
